PCP
ALNY icon

Perbak Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Perbak Capital Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,205
Closed -$399K – 19
2026
Q1 		$399K Buy
+1,205
New +$410K 0.1% 227

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perbak Capital Partners's ALNY Position: Q2 2026 in Review

Perbak Capital Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 1,205 shares — an estimated $399K sold.

Perbak Capital Partners first reported a position in ALNY in Q1 2026 and held it in 1 quarter. The position peaked at $399K in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Perbak Capital Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 1,205 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $399K.
  • Perbak Capital Partners first reported a position in Alnylam Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Perbak Capital Partners's Alnylam Pharmaceuticals position peaked at $399K in Q1 2026.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.